focus -WSS

focus

author：focus 2025-09-27 19:37:09 - browse：83

Sen. Rand Paul (C) (R-KY) questions Homeland Security Secretary Alejandro Mayorkas and FBI Director Christopher Wray during a hearing held by the Senate Homeland Security and Governmental Affairs Committee October 31, 2023 in Washington, DC. — Sen. Rand Paul (R-Ky.) Win McNamee/Getty Images

WASHINGTON — A Senate panel Wednesday passed a bill aimed at preventing certain Chinese companies from doing business in the United States. The sole no vote was by Sen. Rand Paul (R-Ky.), who worries that Congress is using anger toward China as a cover for advancing parochial interests.

Many in Congress are worried the Chinese government and military are using the rising dominance of national companies to gather Americans’ genetic information, which could be used for reasons that range from creating bioweapons to giving China a leg up in drug development.

The Biosecure Act, by Homeland Security and Governmental Affairs Chair Gary Peters (D-Mich.), is a response to those concerns. The bill would block the U.S. government from contracting with companies that do business with Chinese “biotechnology companies of concern,” and it names four companies that must be on that list: BGI Genomics, MGI, Complete Genomics, WuXi AppTec, and any subsidiary, parent affiliate, or successor of these companies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： HIV drugs protect against transmission, even in unprotected sex

WSS

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Stem cell treatment guidelines are released by FDA

NIH nominee Bertagnolli will get October confirmation hearing

Crinetics acromegaly drug succeeds in late

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Wikipedia

focus

hotspot

At least 13 dead in Texas as scorching temps continue

ASCO: Palliative care found as helpful given virtually as in person

23andMe had bad news about my health. I wish a person had delivered it

Trump surgeon general acknowledges mistakes during Covid

In Memoriam: Notable people who died in 2023

Let's speed up science by embracing open access publishing

Supreme Court strikes down use of affirmative action

FDA's Pazdur wants cancer trials to range beyond China alone

Tori Bowie and the unacceptable rates of Black maternal death

The (many) problems with a new study criticizing cancer screening

explore

Intellia reports positive results for its CRISPR

Stem cell treatment guidelines are released by FDA

NIH documents show early flaws of $1.6 billion long Covid program

With trial win, GSK could get blood cancer drug back on market

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Ionis drug prevents swelling attacks due to hereditary angioedema

leisure time

hotspot

entertainment

focus